What the study found
The study found two resistance patterns to neoadjuvant talazoparib, a PARP inhibitor, in triple-negative breast cancer with BRCA1/2 mutations. One involved BRN2 overexpression leading to activation of ATR, RAD51, and STAT3 pathways, while the other involved expansion of a tumor subclone lacking Shieldin 2 (SHLD2) expression.
Why the authors say this matters
The authors conclude that these findings highlight the need to identify both intrinsic and emerging resistance pathways in treatment-naïve tumors. They also say the results support combining PARP inhibitors with targeted agents to improve outcomes in the neoadjuvant setting.
What the researchers tested
The researchers analyzed tumors from a phase II neoadjuvant clinical trial of talazoparib monotherapy in patients with germline BRCA1/2-mutant breast tumors before and after six months of treatment. They performed whole-transcriptome analyses on the patient samples and also created orthotopic patient-derived xenograft models from a subset of tumors for whole-exome and whole-transcriptome analysis.
What worked and what didn't
The integrative analysis revealed both previously known and previously unknown PARP inhibitor resistance mechanisms. BRN2-driven resistance could be reversed with ATR and STAT3 inhibitors, which resensitized cells to talazoparib, while a Shieldin 2-deficient HR-repair-proficient subclone expanded during treatment and accounted for intrinsic resistance.
What to keep in mind
The abstract does not provide detailed limitations beyond noting that neoadjuvant resistance mechanisms are poorly understood. The findings come from a specific clinical trial population with germline BRCA1/2-mutant breast tumors, so the summary does not state how broadly they apply beyond that setting.
Key points
- The study identified two talazoparib resistance routes in neoadjuvant triple-negative breast cancer.
- BRN2 overexpression was linked to activation of ATR, RAD51, and STAT3 pathways.
- ATR and STAT3 inhibitors reversed BRN2-driven resistance in the study models.
- A Shieldin 2-deficient tumor subclone expanded during treatment and was associated with intrinsic resistance.
- The analysis used patient tumors from a phase II trial plus orthotopic patient-derived xenograft models.
Disclosure
- Research title:
- BRN2 and SHLD2-linked resistance emerged during talazoparib treatment
- Authors:
- Noor Mazin Abdulkareem, Yan Jiang, Y. Qi, Xuan Liu, Xiaomei Zhang, Shirong Cai, Jiansu Shao, Sabrina L. Jeter-Jones, Amanda L. Rinkenbaugh, Chun-Chun Cheng, Faiza Baameur Hancock, Jill L. Schwartz, Jennifer K. Litton, Jeffrey T. Chang, H Piwnica-Worms
- Institutions:
- The University of Texas Health Science Center at Houston, The University of Texas Health Science Center at Houston, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center
- Publication date:
- 2026-04-10
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with scholarly research without reading academic papers — one filtered digest, every Friday.